Paraproteinemia and neuropathy

Current Opinion in Neurology

Volumn 12, Issue 5, 1999, Pages 589-595

  Simmons, Zachary ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COLCHICINE; CYTOKINE; IMMUNOGLOBULIN; MELPHALAN; PREDNISONE; RITUXIMAB; VASCULOTROPIN;

BONE MARROW TRANSPLANTATION; CORTICOSTEROID THERAPY; DRUG RESPONSE; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEUROPATHY; PARAPROTEINEMIA; PATHOGENESIS; PLASMAPHERESIS; REVIEW;

AMYLOIDOSIS; CRYOGLOBULINEMIA; HUMANS; MULTIPLE MYELOMA; NERVOUS SYSTEM DISEASES; PARAPROTEINEMIAS; POEMS SYNDROME;

EID: 0033402173     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199910000-00013     Document Type: Review

References (103)

1. 1 Salmon SE, Cassady JR. Plasma cell neoplasms. In: Cancer: principles & practice of oncology, 5th ed. DeVita VT, Hellman S, Rosenberg SA (editors). Philadelphia: Lippincott-Raven; 1997. pp. 2344-2387.
2. 2 Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 1992; 6:347-369.
3. 3 Kelly JJ, Kyle RA, O'Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981; 31:1480-1483.
4. 4 Kahn SN, Riches PG, Kohn J. Paraproteinaemia in neurological disease: incidence, associations, and classification of monoclonal immunoglobulins. J Clin Pathol 1980; 33:617-621.
5. 5 Osby E, Noring L, Hast R, Kjellin KG, Knutsson E, Siden A. Benign monoclonal gammopathy and peripheral neuropathy. Br J Haematol 1982; 51:531-539.
6. 6 Vrethem M, Cruz M, Wen-Xin H, Malm C, Holmgren H, Ernerudh J. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci 1993; 114:193-199.
7. 7 Axelsson U, Bachmann R, Hallen J. Frequency of pathological proteins (M-components) in 6995 sera from an adult population. Acta Med Scand 1966; 179:235-247.
8. 8 Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972; 40:719-724.
9. 9 Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol 1982; 35:63-68.
10. 10 Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993; 43:2202-2209.
11. 11 Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48:321-328.
12. 12 Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995; 118:359-368.
13. 13 Latov N, Sherman WH, Nemni R, Galassi G, Shyong JS, Penn AS, et al. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med 1980; 303:618-621.
14. 14 Nobile-Orazio E, Manfredini E, Carpo M, Meucci N, Monaco S, Ferrari S, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994; 36:416-424.
15. 15 Mendell JR, Sahenk Z, Whitaker JN, Trapp BD, Yates AJ, Griggs RC, Quarles RH. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol 1985; 17:243-254.
16. 16 Hays AP, Lee SSL, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol 1988; 18:231-244.
17. 17 Monaco S, Bonetti B, Ferrari S, Moretto G, Nardelli E, Tedesco F, et al. Complement dependent demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med 1990; 322:844-852.
18. 18 Takatsu M, Hays AP, Latov N, Abrams GM, Nemni R, Sherman WH, et al. Immunofluorescence study of patients with neuropathy and IgM M proteins. Ann Neurol 1985; 81:173-181.
19. 19 Ellie E, Vital A, Steck A, Boiron J-M, Vital C, Julien J. Neuropathy associated with 'benign' anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological, pathological findings and response to treatment in 33 cases. J Neurol 1996; 243:34-43.
20. 20 Vital A, Vital C, Julien J, Baquey A, Steck AJ. Polyneuropathy associated with IgM monoclonal gammopathy: immunological and pathological study in 31 patients. Acta Neuropathol 1989; 79:160-167.
21. 21 Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-asociated glycoprotein. Ann Neurol 1993; 33:502-506.
22. 22 Trojaborg W, Galassi G, Hays AP, Lovelace RE, Alkaitis M, Latov N. Electrophysiological study of experimental demyelination induced by serum of patients with IgM M proteins and neuropathy. Neurology 1989; 39:1581-1586.
23. 23 Hays AP, Latov N, Takatsu M, Sherman WH. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology 1987; 37:242-256.
24. 24 Willison HJ, Trapp BD, Bacher JD, Dalakas MC, Griffin JW, Quarles RH. Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle Nerve 1988; 11:1169-1176.
25. 25 Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 1991; 30:54-61.
26. 26 Suarez GA, Kelly JJ Jr. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Neurology 1993; 43:1304-1308.
27. 27 Nobile-Orazio E, Barbieri S, Baldini L, Marmiroli P, Carpo M, Premoselli S, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand 1992; 85:383-390.
28. 28 Chassande B, Leger J-M, Younes-Chennoufi AB, Bengoufa D, Maisonobe T, Bouche P, Baumann N. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/ electrophysiological features in 40 cases. Muscle Nerve 1998; 21:55-62. This study is helpful in understanding those clinical and electrodiagnostic properties that distinguish patients with anti-MAG and some other antibodies from other patients with IgM monoclonal gammopathies.
29. 29 Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994; 117:941-947.
30. 30 Kelly JJ. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve 1983; 6:504-509.
31. 31 Kelly JJ, Adelman LS, Berkman E, Bhan I. Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol 1988; 45:1355-1359.
32. 32 Hafler DA, Johnson D, Kelly JJ, Panitch H, Kyle R, Weiner HL. Monoclonal gammopathy and neuropathy: myelin-associated glycoprotein reactivity and clinical characteristics. Neurology 1986; 36:75-78.
33. 33 Melmed C, Frail D, Duncan I, Braun P, Danoff D, Finlayson M, Stewart J. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin-associated glycoprotein. Neurology 1983; 33:1397-1405.
34. 34 Nobile-Orazio E, Marmiroli P, Baldini L, Spagnol G, Barbieri S, Moggio M, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 1987; 37:1506-1514.
35. 35 Notermans NC, Wokke JHJ, Lokhorst HM, Franssen H, van der Graaf Y, Jennekens FGI. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: a prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994; 117:1385-1393.
36. 36 Simovic D, Gorson KC, Ropper AH. Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand 1998; 97:194-200. In contrast to some other studies, this paper found no significant clinical differences between the IgM and IgG MGUS patients.
37. 37 Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991; 325:1482-1486.
38. 38 Sherman WH, Olarte MR, McKiernan G, Sweeney K, Latov N, Hays AP. Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. J Neurol Neurosurg Psychiatry 1984; 47:813-819.
39. 39 Hafler DA, Johnson D, Kelly JJ, Panitch H, Kyle R, Weiner HL. Monoclonal gammopathy and neuropathy: myelin-associated glycoprotein reactivity and clinical characteristics. Neurology 1986; 36:75-78.
40. 40 Leger JM, Younes-Chennoufi AB, Chassande B, Davila G, Bouche P, Baumann N, Brunet P. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 1994; 57 (Suppl):46-49.
41. 41 Cook D, Dalakas M, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990; 40:212-214.
42. 42 Ellie E, Vital A, Steck A, Boiron J-M, Vital C, Julien J. Neuropathy associated with 'benign' anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological, pathological findings and response to treatment in 33 cases. J Neurol 1996; 243:34-43.
43. 43 Waterston JA, Brown MM, Ingram DA, Swash M. Cyclosporine A therapy in paraprotein-associated neuropathy. Muscle Nerve 1992; 15:445-448.
44. 44 Oksenhendler E, Chevret S, Leger J-M, Louboutin L-P, Bussel A, Brouet J-C for the IgM-associated polyneuropathy study group. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry 1995; 59:243-247.
45. 45 Haas DC, Tatum AH. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia. Ann Neurol 1988; 23:394-396.
46. 46 Nobile-Orazio E, Baldini L, Barbieri S, Marmiroli P, Spagnol G, Francomano E, Scarlato G. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol 1988; 24:93-97.
47. 47 Mariette X, Chastang C, Clavelou P, Louboutin J-P, Leger J-M, Brouet J-C, for the IgM-associated polyneuropathy study group. A randomised clinical trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 1997; 63:28-34.
48. 48 Rudnicki SA, Harik SI, Dhodapkar M, Barlogie B, Eidelberg D. Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment. Neurology 1998; 51:1210-1213. This report describes the response of anti-MAG neuropathy to autologous bone marrow transplantation.
49. 49 Latov N, Sherman WH. Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with Rituxan. Neurology 1999; 52 (Suppl 2):A551. A novel approach to the treatment of anti-MAG neuropathy with a monoclonal antibody used in non-Hodgkin's lymphoma.
50. 50 Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.
51. 51 Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58:665-683.
52. 52 Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998; 104:232-237. This study refutes the commonly-held assumption that those patients with amyloidosis who present primarily with neuropathy have a good long-term prognosis relative to other patients with amyloidosis.
53. 53 Duston MA, Skinner M, Anderson J, Cohen AS. Peripheral neuropathy as an early marker of AL amyloidosis. Arch Intern Med 1989; 149:358-360.
54. 54 Wang AK, Fealey RD, Gehrking TL, Low PA. Autonomic failure in amyloidosis. Neurology 1999; 52 (Suppl 2):A388. This report characterizes some features of autonomic dysfunction in patients with amyloidosis.
55. 55 Traynor AE, Gertz MA, Kyle RA. Cranial neuropathy associated with primary amyloidosis. Ann Neurol 1991; 29:451-454.
56. 56 Ruiz-Laiglesia FJ, Perez-Calvo JI, Torrubia-Perez CB, Castiella-Muruzabal T, Morandeira-Garcia MJ. Liver failure and peripheral facial paralysis in a case of primary amyloidosis. Arch Intern Med 1998; 158:2066-2067. A case of cranial nerve involvement in amyloidosis, a relatively rare clinical manifestation.
57. 57 Quattrini A, Nemni R, Sferrazza B, Ricevuti G, Dell'Antonio G, Laxxerini A, lannaccone S. Amyloid neuropathy simulating lower motor neuron disease. Neurology 1998; 51:600-602. This case demonstrates that peripheral nervous system involvement in amyloidosis may begin very atypically before assuming the clinical and electrodiagnostic features seen more commonly.
58. 58 Kyle RA, Dyck PJ. Amyloidosis and neuropathy. In: Peripheral neuropathy, 3rd ed. Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (editors). Philadelphia: WB Saunders; 1993. pp. 1294-1309.
59. 59 Janssen S, Van Rijswijk MH, Meijer S, Ruinen L, Van Der Hem GK. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 1986; 29:376-385.
60. 60 Simmons Z, Blaivas M, Aguilera AJ, Feldman EL, Bromberg MB, Towfighi J. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. J Neurol Sci 1993; 120:60-63.
61. 61 Wokke JHJ, Morris JH, Donaghy M. Lymphoma, paraproteinaemia, and neuropathy. J Neurol Neurosurg Psychiatry 1996; 60:684-689.
62. 62 Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336:1202-1207.
63. 63 Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101:766-769. This therapy is very toxic, but may be appropriate for some patients with amyloidosis.
64. 64 Gillmore JD, Davies J, Iqbal A, Madhoo S, Russell NH, Hawkins PN. Allogenic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol 1998; 100:226-228. This report describes complete clinical recovery in a disease that is generally poorly responsive to treatment.
65. 65 Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93:1062-1066. This paper highlights prolonged survival in a small group of patients with amyloidosis, but concludes that peripheral neuropathy is an unfavorable rather than a favorable prognostic feature, thus refuting conventional wisdom.
66. 66 Steck AJ. Neurological manifestations of malignant and non-malignant dysglobulinaemias. J Neurol 1998; 245:634-639. This brief, general review can be read quickly and provides a good overview of the topic.
67. 67 Ciompi ML, Marini D, Siciliano G, Melchiorre D, Bazzichi L, Sartucci F, Murri L. Cryoglobulinemic peripheral neuropathy: neurophysiologic evaluation in twenty-two patients. Biomed Pharmacother 1996; 50:329-336.
68. 68 Logothetis J, Kennedy WR, Ellington A, Williams R. Cryoglobulinemic neuropathy. Arch Neurol 1968; 19:389-397.
69. 69 Garcia-Bragado F, Fernandez JM, Navarro C, Villar M, Bonaventura I. Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol 1988; 45:1210-1214.
70. 70 Valli G, De Vecchi A, Gaddi L, Nobile-Orazio E, Tarantino A, Barbieri S. Peripheral nervous system involvement in essential cryoglobulinemia and nephropathy. Clin Exp Rheumatol 1989; 7:479-483.
71. 71 Ferri C, La Civita L, Cirafisi C, Siciliano G, Longombardo G, Bombardieri S, Rossi B. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol 1992; 19:889-895.
72. 72 Gemignani F, Pevesi G, Fiocchi A, Manganelli P, Ferraccioli G, Marbini A. Peripheral neuropathy in essential mixed cryoglobulinemia. J Neurol Neurosurg Psychiatry 1992; 55:116-120.
73. 73 Scelsa SN, Herskovitz S, Reichler B. Treatment of mononeuropathy multiplex in hepatitic C virus and cryoglobulinemia. Muscle Nerve 1998; 21:1526-1529. This report emphasizes the worsening that may occur when cryoglobulinemic neuropathy is treated with interferon-α.
74. 74 Harle JR, Disdier P, Pelletier J, Azulay JP, Perreard M, Weiller PJ, Jouglard J. Dramatic worsening of hepatitis C virus-related cryoglobulinemia subsequent to treatment with interferon alpha [letter]. JAMA 1995; 274:126.
75. 75 La Civita L, Zignego AL, Lombardini F, Monti M, Longombardo G, Pasero G, Ferri C. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol 1996; 23:1641-1643.
76. 76 Khella SL, Frost S, Hermann GA, Leventhal L, Whyatt S, Sajid MA, Scherer SS. Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy. Treatment with interferon alfa: case report and literature review. Neurology 1995; 45:407-411.
77. 77 David WS, Peine C, Schlesinger P, Smith SA. Nonsystemic vasculitic mononeuropathy multiplex, cryoglobulinemia, and hepatitis C. Muscle Nerve 1996; 19:1596-1602.
78. 78 Apartis E, Leger JM, Musset L, Gugenheim M, Cacoub P, Lyon-Caen O, et al. Peripheral neuropathy associated with essential mixed cryoglobulinemia: a role for hepatitis C virus infection? J Neurol Neurosurg Psychiatry 1996; 60:661-666.
79. 79 Dumitru D. Electrodiagnostic medicine. Philadelphia: Hanley & Belfus; 1995. pp. 788-789.
80. 80 Ferri C, Marzo E, Longombardo G, Lombardini F, Greco F, Bombardieri S. Alpha-interferon in the treatment of mixed cryoglobulinemia patients. Eur J Cancer 1991; 27 (Suppl 4):S81-S82.
81. 81 Kelly JJ, Kyle RA, Miles JM, O'Brien PC, Dyck PJ. The spectrum of peripheral neuropathy in myeloma. Neurology 1981; 31:24-31.
82. 82 Kelly JJ, Kyle RA, Miles JM, Dyck PJ. Osteosclerotic myeloma and peripheral neuropathy. Neurology 1983; 33:202-210.
83. 83 Kyle RA, Dyck PJ. Osteosclerotic myeloma (POEMS syndrome). In: Peripheral neuropathy, 3rd ed. Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (editors). Philadelphia: WB Saunders; 1993. pp 1288-1293.
84. 84 Soubrier MJ, Dubost J-J, Sauvezie BJM, and the French Study Group on POEMS syndrome. POEMS syndrome: a study of 25 cases and a review of the literature. Am J Med 1994; 97:543-553.
85. 85 Pavord SR, Murphy PT, Mitchell VE. POEMS syndrome and Waldenstrom's macroglobulinaemia. J Clin Pathol 1996; 49:181-182.
86. 86 Simmons Z, Wald J, Albers JW, Feldman EL. The natural history of a 'benign' rib lesion in a patient with a demyelinating polyneuropathy and an unusual variant of POEMS syndrome. Muscle Nerve 1994; 17:1055-1059.
87. 87 Takatsuki K, Sanada I. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol 1983; 13:543-556.
88. 88 Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy: the spectrum of POEMS syndrome. N Engl J Med 1992; 327:1919-1923.
89. 89 Nakanishi T, Sobue I, Toyokura Y, Nishitani H, Kuroiwa Y, Satoyoshi E, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 1984; 34:712-720.
90. 90 Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Medicine 1980; 59:311-322.
91. 91 Driedger H, Pruzanski W. Plasma cell neoplasia with peripheral polyneuropathy: a study of five cases and a review of the literature. Medicine 1980; 59:301-310.
92. 92 Read D, Warlow C. Peripheral neuropathy and solitary plasmacytoma. J Neurol Neurosurg Psychiatry 1978; 41:177-184.
93. 93 Adams D, Said G. Ultrastructural characterisation of the M protein in nerve biopsy of patients with POEMS syndrome. J Neurol Neurosurg Psychiatry 1998; 64:809-812. This review provides support for a direct role of the IgM monoclonal protein in the pathogenesis of neuropathy in POEMS syndrome.
94. 94 Soubrier M, Dubost J-J, Serre AF, Ristori J-M, Sauvezie B, Cathebras P, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum 1997; 40:786-787.
95. 95 Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998; 21:1390-1397. This paper addresses the possible pathogenetic role of VEGF in causing some of the varied features of the POEMS syndrome by demonstrating elevated levels in a series of these patients.
96. 96 Soubrier M, Guillon R, Dubost J-J, Serre AF, Ristori J-M, Boyer L, Sauvezie B. Arterial obliteration in POEMS syndrome: possible role of vascular endothelial growth factor. J Rheumatol 1998; 25:813-815. This single case supports the role of VEGF in the pathogenesis of POEMS syndrome.
97. 97 Lesprit P, Godeau B, Authier F-J, Soubrier M, Zuber M, Larroche C, et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 1998; 157:907-911. This paper studies pulmonary hypertension as a part of the multiorgan involvement in POEMS syndrome, and discusses the possible pathogenetic role of cytokines.
98. 98 Lesprit P, Authier F-J, Gherardi R, Belec L, Paris D, Melliere D, et al. Acute arterial obliteration: a new feature of the POEMS syndrome? Medicine 1996; 75:226-232.
99. 99 Bova G, Pasqui AL, Saletti M, Bruni F, Auteri A. POEMS syndrome with vascular lesions: a role for interleukin-1beta and interleukin-6 increase. Angiology 1998; 49:937-940. This case report reinforces the possible role of cytokines in the pathogenesis of POEMS syndrome.
100. 100 Kuwabara S, Hattori T, Shimoe Y, Kamitsukasa I. Long term melphalan-prednisolone chemotherapy for POEMS syndrome. J Neurol Neurosurg Psychiatry 1997; 63:385-387.
101. 101 Benito-Leon J, Lopez-Rios F, Rodriguez-Martin FJ, Madero S, Ruiz J. Rapidly deteriorating polyneuropathy associated with osteosclerotic myeloma responsive to intravenous immunoglobulin and radiotherapy. J Neurol Sci 1998; 158:113-117. This patient with POEMS may have responded to IVIg, or may simply have improved because of radiation to the bone lesion.
102. 102 Henze T, Krieger G. Combined high-dose 7S-IgG and dexamethasone is effective in severe polyneuropathy of the POEMS syndrome. J Neurol 1995; 242:482-483.
103. 103 Huang CC, Chu CC. Poor response to intravenous immunoglobulin therapy in patients with Castleman's disease and the POEMS syndrome. J Neurol 1996; 243:726-727.